Cyclin D as a therapeutic target in cancer.
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
|Authors||Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L.|
|Responsible Garvan Author||(missing name)|
|Publisher Name||NATURE REVIEWS CANCER|
|DOI||nrc3090 [pii] 10.1038/nrc3090|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21734724|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/10994|